Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

Julie Graff, Celestia S. Higano, Noah M. Hahn, Matthew Taylor, Bin Zhang, Xiaofei Zhou, Karthik Venkatakrishnan, E. Jane Leonard, John Sarantopoulos

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint Dive into the research topics of 'Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences